Santhera Pharmaceuticals Holding AG's EBIT per Share for the
six
months ended in Dec. 2025 was CHF-0.27.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-2.92.
During the past 3 years, the average EBIT per Share Growth Rate was 30.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
XSWX:SANN'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -68.3 Med: 20.4 Max: 44.1
Current: 30.3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Santhera Pharmaceuticals Holding AG was 44.10% per year. The lowest was -68.30% per year. And the median was 20.40% per year.
XSWX:SANN's 3-Year EBIT Growth Rate is ranked better than 68.42% of 1178
companies
in the Biotechnology industry
Industry Median: 15.55
vs XSWX:SANN: 30.30
Santhera Pharmaceuticals Holding AG (XSWX:SANN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Santhera Pharmaceuticals Holding AG EBIT per Share Related Terms
Santhera Pharmaceuticals Holding AG EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-2.92
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG (XSWX:SANN) has a EBIT per Share of CHF-2.92 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #372 out of 1178 companies in the Biotechnology industry, placing it in the top 31.6%.
Is Santhera Pharmaceuticals Holding AG's EBIT per Share too high?
Santhera Pharmaceuticals Holding AG's current EBIT per Share is CHF-2.92. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #372 out of 1178 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #372 out of 1178 companies for EBIT per Share. This puts Santhera Pharmaceuticals Holding AG in the upper half of its industry. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,178 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santhera Pharmaceuticals Holding AG's current EBIT per Share is CHF-2.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (XSWX:SANN) is currently considered Possible Value Trap. The stock's GF Value™ is CHF23.24, compared to a current price of CHF15.20 — trading 34.6% below its estimated fair value. The current EBIT per Share is CHF-2.92. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (XSWX:SANN), the current EBIT per Share is CHF-2.92 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santhera Pharmaceuticals Holding AG (XSWX:SANN) Overvalued in 2026?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued.
The current stock price of CHF15.20 is trading 34.6% below its estimated GF Value™ of CHF23.24.
GuruFocus considers Santhera Pharmaceuticals Holding AG to be Possible Value Trap.
Key valuation signals for XSWX:SANN:
EBIT per Share: CHF-2.92
GF Value™: CHF23.24 vs. price of CHF15.20 (34.6% below fair value)
No single metric tells the full story. See the XSWX:SANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santhera Pharmaceuticals Holding AG Business Description
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score
Get the complete analysis for XSWX:SANN
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SANN has been successfully added to your 
